** Shares of drug developer Immunic rise 20% to $1.86 premarket
** Co says an independent data monitoring committee has recommended continuing its late-stage trial for an experimental multiple sclerosis drug without changes
** The drug, vidofludimus calcium, is being tested in patients with multiple sclerosis, a chronic autoimmune disease that affects the central nervous system
** The committee has recommended the trial is not futile and should continue as planned after an interim analysis - IMUX
** Co expects the study to be completed in 2026
** Up to last close, stock up 3.3% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。